Archive
589 articles, sorted by publication time.
A Nature Immunology study rewrites the role of MHC I in anticancer immunity: when cancer cells lose this identity card, they may not only evade killer T cells, but also become exposed to ferroptosis pressure triggered by helper T cells.
SLAMF6 may cause cancer-fighting T cells to gradually burn out on the battlefield; blocking this self-activating molecular signal offers a new drug target for extending the immune attack, but clinical proof remains some distance away.
Isomorphic Labs says its AI drug design pipeline is moving toward first-in-human trials; the real question is no longer only whether models can design molecules, but whether these candidates can pass through the narrow gate of clinical testing, safety, and regulation.
A Cell study links part of Alzheimer’s disease risk to cancer-driving mutations that accumulate in aging blood cells; this does not mean dementia is cancer, but it does prompt scientists to re-examine the channels between blood, brain immunity, and chronic inflammation.
A new study shifts the focus from plaques outside the brain’s cells to the transport system inside cells, proposing a possible mechanism in which amyloid beta and tau compete for positions on microtubules; it is not yet conclusive, but it offers a more specific biological pathway for a long-standing unresolved protein relationship.
A prospective study published in Radiology shows that transarterial embolization, which blocks abnormal inflammatory blood flow in the knee, can relieve pain for most patients with knee osteoarthritis for at least one year. It is not a shortcut to curing joint wear, but it could change the treatment ladder before surgery.
Drugs such as Ozempic and Wegovy are moving from metabolic medicine into more complex behavioral science; a new study raises an intriguing but still unsettled signal: they may not eliminate impulses, but may weaken the step by which impulse turns into violence.
A new benchmark test for preclinical pharmacology decisions shows that AI agents can read data and run workflows, but still struggle to consistently make trusted drug development judgments.
The FDA has approved Hepcludex for some adults with chronic hepatitis D, opening the first regulatory pathway for an infection that has long lacked an approved treatment; but accelerated approval also means that whether efficacy can translate into long-term clinical benefit still needs to be answered by subsequent data.
An Australian team’s study shifts the focus from simply attacking amyloid proteins to repairing the blood-brain barrier’s “waste-removal pump”; the results are promising, but the evidence remains limited to experimental animals.
As parents search for any possible way forward on a long caregiving road, costly umbilical cord stem cell infusions are being packaged as hope; but existing clinical evidence does not yet support routine use, and regulatory warnings are clearer than promises of efficacy.
A UC Berkeley team has found in methane-producing archaea that the UAG codon, which usually means “stop,” is sometimes reread as a rare amino acid, opening a measurable gap in one of life’s most stable translation rules.